Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

Table 2

Clinical data on DEB-TACE.

Variables	Data
Inpatient duration, days	10.0 (8.0, 14.0)
Oxaliplatin, mg	94.4 ± 15.2
Lobaplatin, mg	21.5 ± 4.3
Hospitalization cost, ×10^4 ¥	5.9 ± 2.2
DEB-TACE procedures	1.9 ± 1.3
Additional embolization
Gelatin sponge particles	10 (24.4%)
Embolization microspheres	2 (4.9%)
Polyvinyl alcohol particles	4 (9.8%)
Complications, n (%)	21 (51.2%)
Fever	4 (9.8%)
Nausea	12 (29.3%)
Vomiting	2 (4.9%)
Leukopenia	5 (12.2%)
Abdominal pain	20 (48.8%)
Raised ALT/AST	3 (7.3%)
Other interventional treatments, n (%)	13 (31.7%)
Conventional TACE	11 (26.8%)
^125I seeds implantation	2 (4.9%)
Thermal ablation	4 (9.8%)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TACE, transcatheter arterial chemoembolization.